

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Attorney Docket Number</b>	4239-61725
	<b>Application Number</b>	09/830,748
	<b>Filing Date</b>	April 30, 2001
	<b>First Named Inventor</b>	Kashmiri
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Larry Ronald Helms

### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
LAH		5,994,511	11/30/99	Lowman <i>et al.</i>
LAH		6,054,297	4/25/00	Carter <i>et al.</i>
LAH		6,180,370	1/30/01	Queen <i>et al.</i>

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
LAH		WO 96/13594	5/9/96	
LAH		WO 97/26010	7/24/97	
LAH		WO 99/43816	9/2/99	

### OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
LAH		Hakimi <i>et al.</i> , "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," <i>J. Immunol.</i> 147:1352-1359, 1991.
		Iwahashi <i>et al.</i> , "CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity," <i>Mol. Immunol.</i> 36:1079-1091:1999.
		Kashmiri <i>et al.</i> , "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," <i>Crit. Rev. Oncol. Hematol.</i> 38:3-16, 2001.
		Kashmiri <i>et al.</i> , "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," <i>Hybridoma</i> 14:461-473, 1995.
		Padlan, "Anatomy of the antibody molecule," <i>Mol. Immunol.</i> 31:169-217, 1994.
LAH		Reichman <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature (London)</i> 332:323-327, 1988.

EXAMINER  
SIGNATURE:




DATE  
CONSIDERED:

4/17/04

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney Docket Number</b>	4239-61725
		<b>Application Number</b>	09/830,748
		<b>Filing Date</b>	April 30, 2001
		<b>First Named Inventor</b>	Kashmiri
		<b>Art Unit</b>	1642
		<b>Examiner Name</b>	Larry Ronald Helms
LA		Saldanha <i>et al.</i> , "A single backmutation in the human kLV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Mol. Immunol.</i> 36:709-719, 1999.	
		Schier <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J. Mol. Biol.</i> 263:551-567, 1996.	
		Sha and Xiang, "A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen," <i>Cancer Biother.</i> 9:341-349, 1994.	
		Sharkey <i>et al.</i> , "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> 55:5935s-5945s.	
		Slavin-Chiorini <i>et al.</i> , "Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins," <i>Cancer Res.</i> 55(23 Suppl.):5957s-5967s, 1995.	
		Slavin-Chiorini <i>et al.</i> , "A CDR-grafted (humanized) domain-deleted antitumor antibody," <i>Cancer Biother. Radiopharm.</i> 12:305-316, 1997.	
		Tamura <i>et al.</i> , "Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only," <i>J. Immunol.</i> 164:1432-1441, 2000.	
		Wu <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294:151-162, 1999.	
		Xiang <i>et al.</i> , "Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG-72 antigen interaction," <i>Protein Eng.</i> 9:539-543, 1996.	
		Xiang <i>et al.</i> , "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," <i>Protein Eng.</i> 12:417-421, 1999.	
		Xiang <i>et al.</i> , "The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen," <i>Cancer Biother.</i> 8:253-262, 1993.	

<b>EXAMINER SIGNATURE:</b> 	<b>DATE CONSIDERED:</b> 4/19/03
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	